New method aims to improve lung transplant access for hard-to-match candidates

The FDA hand­ed a com­plete re­sponse let­ter to Mesoblast for its BLA sub­mis­sion of its drug for pe­di­atric steroid-re­frac­to­ry acute graft-ver­sus-host dis­ease (SR-aGVHD), the com­pa­ny

Hu­mi­ra isn’t go­ing any­where yet. And its suc­ces­sors are com­ing along nice­ly, too. On Thurs­day, Ab­b­Vie shared sec­ond-quar­ter fi­nan­cial re­sults that show its cor­ner­stone im­munol­o­gy